Richter syndrome (RS) refers to the clinical process of disease progression and transformation to aggressive lymphoma on the basis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). RS transformation is a clinical manifestation of the progression of malignant hematological diseases, and it suggests a poor prognosis when the patient has RS transformation. Currently, there is no uniform standard for RS treatment worldwide. In this paper, the treatment regimens and prognosis of two cases with RS who transformed from CLL to diffuse large B-cell lymphoma (DLBCL) are retrospectively analyzed, and the possibility of treating RS with hematopoietic stem cell transplantation or chimeric antigen receptor T cell (CAR-T) immunotherapy after chemotherapy is discussed, in order to provide a reference for the clinical practice.

1.Condoluci A, Rossi D. Richter Syndrome[J]. Curr Oncol Rep, 2021, 23(3): 26. DOI: 10.1007/s11912-020-01001-x.

2.Thompson PA, Siddiqi T. Treatment of Richter's syndrome[J]. Hematology Am Soc Hematol Educ Program, 2022, 2022(1): 329-336. DOI: 10.1182/hematology.2022000345.

3.Bouclet F, Calleja A, Dilhuydy MS, et al. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort[J]. Ann Hematol, 2021, 100(4): 987-993. DOI: 10.1007/s00277-021-04419-w.

4.Condoluci A, Rossi D. Biology and treatment of Richter transformation[J]. Front Oncol, 2022, 12: 829983. DOI: 10.3389/fonc.2022.829983.

5.Croizier C, Guieze R. Richter syndrome: diagnostic and therapeutic management[J]. Bull Cancer, 2021, 108(5): 521-527. DOI: 10.1016/j.bulcan.2021.01.014.

6.遆娟娟,白波,马梁明. Richter综合征诊治进展  [J]. 中国肿瘤临床, 2018, 45(23): 1230-1233. [Ti JJ, Bai  B, Ma LM. Progress in the diagnosis and treatment of Richter syndrome[J]. Chinese Journal of Clinical Oncology, 2018, 45(23): 1230-1233.] DOI: 10.3969/j.issn.1000-8179. 2018.23.188.

7.Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome[J]. Blood, 2018, 131(25): 2761-2772. DOI: 10.1182/blood-2018-01-791376.

8.Parry EM, Leshchiner I, Guièze R, et al. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome[J]. Nat Med, 2023, 29(1): 158-169. DOI: 10.1038/s41591-022-02113-6.

9.Wang Y, Sinha S, Wellik LE, et al. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome[J]. Blood Cancer J, 2021, 11(5): 86. DOI: 10.1038/s41408-021-00477-5.

10.Albano D, Calabrò A, Dondi F, et al. 2-[18F]-FDG PET/CT semiquantitative and radiomics predictive parameters of Richter's transformation in CLL patients[J]. Medicina (Kaunas), 2024, 60(2): 203. DOI: 10.3390/medicina 60020203.

11.Hampel PJ, Rabe KG, Call TG, et al. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib[J]. Blood Cancer J, 2022, 12(9): 124. DOI: 10.1038/s41408-022-00721-6.

12.Graf SA, Cassaday RD, Morris K, et al. Ibrutinib monotherapy in relapsed or refractory, transformed diffuse large B-cell lymphoma[J]. Clin Lymphoma Myeloma Leuk, 2021, 21(3): 176-181. DOI: 10.1016/j.clml.2020.11.023.

13.王赫男,王亮. BCL-2抑制剂在血液系统恶性肿瘤中的研究进展[J]. 中国癌症防治杂志, 2021, 13(4): 344-351. [Wang HN, Wang L. Research progress of BCL- 2 inhibitors in hematological malignancies[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(4): 344-351.] DOI: 10.3969/j.issn.1674-5671.2021.04.03.

14.Izutsu K, Yamamoto K, Kato K, et al. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma[J]. Int J Hematol, 2021, 113(3): 370-380. DOI: 10.1007/s12185-020-03024-3.

15.Davids MS, Rogers KA, Tyekucheva S, et al. Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome[J]. Blood, 2022, 139(5): 686-689. DOI: 10.1182/blood. 2021011386.

16.Herrera AF, Ahn KW, Litovich C, et al. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome[J]. Blood Adv, 2021, 5(18): 3528-3539. DOI: 10.1182/bloodadvances.2021004865.

17.Barbanti MC, Appleby N, Kesavan M, et al. Cellular therapy in high-risk relapsed/refractory chronic lymphocytic leukemia and Richter syndrome[J]. Front Oncol, 2022, 12: 888109. DOI: 10.3389/fonc.2022. 888109.

18.Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors[J]. N Engl J Med, 2020, 382(6): 545-553. DOI: 10.1056/NEJMoa1910607.

19.Marofi F, Rahman HS, Achmad MH, et al. A deep insight into CAR-T cell therapy in non-hodgkin lymphoma: application, opportunities, and future directions[J]. Front Immunol, 2021, 12: 681984. DOI: 10.3389/fimmu.2021. 681984.

20.Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma[J]. N Engl J Med, 2022, 386(7): 640-654. DOI: 10.1056/NEJMoa2116133.

21.Tian L, Li C, Sun J, et al. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: a systematic review[J]. Front Immunol, 2023, 13: 1041177. DOI: 10.3389/fimmu.2022.1041177.

22.Ernst M, Oeser A, Besiroglu B, et al. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma[J]. Cochrane Database Syst Rev, 2021, 9(9): CD013365. DOI: 10.1002/ 14651858.CD013365.pub2.

23.应志涛,林宁晶,吴梦,等. 北京大学肿瘤医院嵌合抗原受体T细胞治疗淋巴瘤全流程管理原则[J]. 白血病·淋巴瘤, 2021, 30(11): 674-684. [Ying ZT, Lin NJ, Wu M, et al. The whole process management principles of chimeric antigen receptor T-cell therapy for lymphoma at Peking University Cancer Hospital[J]. Journal of Leukemia and Lymphoma, 2021, 30(11): 674-684.] DOI: 10.3760/cma.j.cn115356-20210923-00227.

24.Shadman M, Pasquini M, Ahn KW, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission[J]. Blood, 2022, 139(9): 1330-1339. DOI: 10.1182/blood.2021013289.